The pathology group can be AI PathAI has been part of a pharmaceutical company for many years with pharma giant GlaxoSmithKline.
The agreement will focus on strengthening clinical trials and the development of a drug in oncology and for nonlcoholic steatohepatitis (NASH), a serious form of fatty liver disease that can lead to liver disease and liver failure.
“Our team will partner with GSK and PathAI’s AI and platform engineering teams to improve algorithm development until new information is identified that can be quickly applied to clinical trials,” he said. and PathAI CEO and cofounder Andrew Beck in a statement.
“Together, we hope to use the power of machine learning to predict which patients will benefit from medications in critical areas.”
Why it is
This isn’t GSK’s first collaboration with healthcare and medical technology startups. The company recently passed away expanded its pharmaceutical knowledge company with 23andMe until July 2023. That partnership first began in 2018 when GSK poured $ 300 million into the consumer genetics company.
Last year, GSK was also there has expanded its collaboration with Viome Life Sciences to study the relationship between the gut microbiome and certain diseases, such as autoimmune diseases. Their meeting began in 2019 with a focus on the role of stomach health in preventing heart disease.
GSK is introducing the latest agreement as an alternative way for professional education to improve the medical knowledge process.
“GSK is using the world’s leading AI / ML, with our dedicated facility in Ladana, a predictive and data -driven approach to drug discovery and clinical trials with a view to improving to the exact numbers of new medicines.
“We look forward to using PathAI’s knowledge and dual features to advance GSK’s proprietary AI models and focus on developing better features to provide better treatment options for patients with diabetes mellitus and NASH, ”Kim Branson, SVP, world head of artificial intelligence and machine learning at GSK, said in a statement.
THE GREAT WORK
PathAI also recruited colleagues to use its technology. In October, the launch came has a significant partnership with Roche’s medical and diagnostics team to develop and distribute its AI pathology technology through Roche’s ePath business program, a platform for labs.
Last month, PathAI partnered with the Cleveland Clinic to use its algorithms for medical care and research.
Now, the pathology is a difficult year to start. In May 2021, it closed a $ 165 million Series C funding, bringing the total to $ 255 million. It has Poplar Healthcare Management to integrate lab testing services into its offerings.